Publications by authors named "C J Laflamme"
Antibody-based research applications are critical for biological discovery. Yet there are no industry standards for comparing the performance of antibodies in various applications. We describe a knockout cell line-based antibody characterization platform, developed and approved jointly by industry and academic researchers, that enables the systematic comparison of antibody performance in western blot, immunoprecipitation and immunofluorescence.
View Article and Find Full Text PDFArticle Synopsis
- - The TREAT-AD program aims to create reliable tools for testing hypotheses related to Alzheimer's disease, emphasizing the need for validated research antibodies used in experiments involving drug targets.
- - Researchers assessed several commercial antibodies targeting specific proteins (Moesin, CD44, Midkine, and sFRP-1) using Western blot analysis on brain tissues from a mouse model with Alzheimer's pathology.
- - The study found significant increases in the expression of these target proteins in the Alzheimer's model compared to control mice, confirming the antibodies' effectiveness for future research on Alzheimer's therapeutics.
Phosphatidylinositol-specific phospholipase C gamma 2 (PLC-gamma-2) is an enzyme that regulates the function of immune cells. PLC-gamma-2 has been implicated in neurodegenerative and autoimmune disorders, yet investigation of this protein has been limited by a lack of independently characterized antibodies. Here we have characterized eleven PLC-gamma-2 commercial antibodies for use in Western Blot, immunoprecipitation, and immunofluorescence using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls.
View Article and Find Full Text PDFArticle Synopsis
- * This study evaluated ten commercial antibodies against CSNK2A1 for their effectiveness in techniques like western blot and immunofluorescence, using rigorous experimental methods that include comparisons with knockout cell lines.
- * The research is part of a wider effort to enhance antibody reproducibility and provides open-access findings to support scientists in choosing the best antibodies for their experiments.
The amyloid-beta precursor protein is a transmembrane protein expressed in many tissues and highly concentrated in the brain. The protein is of significant interest due to its involvement in the generation of amyloidogenic β-amyloid peptides, prone to plaque formation that is characteristic of Alzheimer's Disease. The scientific community would benefit from the availability of high-quality anti-amyloid-beta precursor protein antibodies to enhance reproducible research on this target.
View Article and Find Full Text PDF